Literature DB >> 18926712

Clinical study of modified Ivor-Lewis esophagectomy plus adjuvant radiotherapy for local control of stage IIA squamous cell carcinoma in the mid-thoracic esophagus.

Gang Chen1, Zhou Wang, Xiang-Yan Liu, Ming-Yue Zhang, Fan-Ying Liu.   

Abstract

OBJECTIVE: To control the postoperative local recurrence is one of the critical factors to improve prognosis of patients with esophageal carcinoma. The aim of this study is to evaluate the effectiveness of modified Ivor-Lewis esophagectomy plus adjuvant radiotherapy for local control of stage IIA squamous cell carcinoma in the mid-thoracic esophagus.
METHODS: One hundred and twenty-five patients with stage IIA mid-thoracic esophageal squamous cell carcinoma who underwent modified Ivor-Lewis esophagectomy between June 1999 and June 2002 were included in the retrospective analysis. All the patients were evaluated within 3 years after surgery to detect tumor recurrence. Kaplan-Meier method was used to calculate the survival rate and logistic regression analysis was performed to identify risk factors of locoregional recurrence.
RESULTS: The overall 3-year and 5-year survival rate in all patients was 58.4% and 43.2%, respectively. Tumor recurrence occurred in 61 patients (48.8%) within 3 years after operation. The median disease-free interval was 12.6 months. Thirty-three patients (26.4%) developed locoregional recurrence, 23 patients (18.4%) developed distant recurrence and 5 patients (4.0%) developed locoregional and distant recurrence simultaneously. Locoregional recurrence rate of patients with postoperative radiotherapy was significantly lower than that of those without postoperative radiotherapy (p<0.05). Logistic regression analysis showed that adjuvant radiotherapy (p=0.007) was an independent risk factor for tumor locoregional recurrence. Cox regression analysis showed that locoregional recurrence but not adjuvant radiotherapy was a relevant prognostic factor of patients with stage IIA esophageal cancer.
CONCLUSIONS: Modified Ivor-Lewis esophagectomy with two-field lymph node dissection plus adjuvant radiotherapy might be an effective strategy to achieve local control of stage IIA mid-thoracic esophageal squamous cell carcinoma.

Entities:  

Mesh:

Year:  2008        PMID: 18926712     DOI: 10.1016/j.ejcts.2008.09.002

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  11 in total

1.  Prognostic significance of Ku80 in pT2N0M0 esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy.

Authors:  Shuai Wang; Zhou Wang; Xiangyan Liu; Yu Yang; Mo Shi; Zhenguo Sun
Journal:  Tumour Biol       Date:  2015-03-11

2.  Overexpression of Ku80 suggests poor prognosis of locally advanced esophageal squamous cell carcinoma patients.

Authors:  Shuai Wang; Zhou Wang; Xiangyan Liu; Yu Liu; Yang Jia
Journal:  World J Surg       Date:  2015-07       Impact factor: 3.352

3.  Clinical usefulness of 18F-FDG PET/CT in the restaging of esophageal cancer after surgical resection and radiotherapy.

Authors:  Long Sun; Xin-Hui Su; Yong-Song Guan; Wei-Ming Pan; Zuo-Ming Luo; Ji-Hong Wei; Long Zhao; Hua Wu
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

4.  TNFAIP8 overexpression: a potential predictor of lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma after Ivor Lewis esophagectomy.

Authors:  Zhenguo Sun; Xiangyan Liu; Jee Hoon Song; Yulan Cheng; Yu Liu; Yang Jia; Stephen J Meltzer; Zhou Wang
Journal:  Tumour Biol       Date:  2016-02-17

5.  The role of postoperative radiotherapy for radically resected esophageal squamous cell carcinoma: a systemic review and meta-analysis.

Authors:  Tingting Liu; Wen Liu; Hongwei Zhang; Chengbo Ren; Jun Chen; Jun Dang
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

6.  Postoperative Radiotherapy in Pathological T2-3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study.

Authors:  Wei Deng; Jinsong Yang; Wenjie Ni; Chen Li; Xiao Chang; Weiming Han; Zongmei Zhou; Dongfu Chen; Qinfu Feng; Jun Liang; Jima Lv; Xiaozhen Wang; Xin Wang; Lei Deng; Wenqing Wang; Nan Bi; Tao Zhang; Yexiong Li; Shugeng Gao; Qi Xue; Yousheng Mao; Kelin Sun; Xiangyang Liu; Dekang Fang; Dali Wang; Jian Li; Jun Zhao; Kang Shao; Zhishan Li; Xinjie Chen; Lei Han; Lifang Wang; Jie He; Zefen Xiao
Journal:  Oncologist       Date:  2020-02-21

7.  Overexpression of IFITM3 predicts the high risk of lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy.

Authors:  Yang Jia; Miao Zhang; Wenpeng Jiang; Zhiping Zhang; Shiting Huang; Zhou Wang
Journal:  PeerJ       Date:  2015-10-29       Impact factor: 2.984

8.  Overexpression of IFITM3 predicts poor prognosis in stage IIA esophageal squamous cell carcinoma after Ivor Lewis esophagectomy.

Authors:  Yang Jia; Zhaohua Xiao; Wenpeng Jiang; Gang Chen; Zhou Wang
Journal:  Thorac Cancer       Date:  2017-08-30       Impact factor: 3.500

9.  CEP55 promotes the proliferation, migration and invasion of esophageal squamous cell carcinoma via the PI3K/Akt pathway.

Authors:  Yang Jia; Zhaohua Xiao; Xin Gongsun; Zhongwei Xin; Bin Shang; Gang Chen; Zhou Wang; Wenpeng Jiang
Journal:  Onco Targets Ther       Date:  2018-07-20       Impact factor: 4.147

10.  Difference in failure patterns of pT3-4N0-3M0 esophageal cancer treated by surgery vs surgery plus radiotherapy.

Authors:  Ya Zeng; Wen Yu; Qi Liu; Wei-Wei Yu; Zheng-Fei Zhu; Wei-Xin Zhao; Jun Liu; Jia-Ming Wang; Xiao-Long Fu; Yuan Liu; Xu-Wei Cai
Journal:  World J Gastrointest Oncol       Date:  2019-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.